2020
DOI: 10.3390/cancers12071733
|View full text |Cite
|
Sign up to set email alerts
|

RORα Regulates Cholesterol Metabolism of CD8+ T Cells for Anticancer Immunity

Abstract: Retinoic acid-related orphan receptor α (RORα) functions as a transcription factor for various biological processes, including circadian rhythm, inflammation, cancer, and lipid metabolism. Here, we demonstrate that RORα is crucial for maintaining cholesterol homeostasis in CD8+ T cells by attenuating NF-κB transcriptional activity. Cholesterol sulfate, the established natural agonist of RORα, exhibits cellular cytotoxicity on, and increased effector responses in, CD8+ T cells. Transcript analysis revea… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
17
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 33 publications
(21 citation statements)
references
References 58 publications
2
17
0
Order By: Relevance
“…Conssistent with a previous report, when co-infused TRP-1 Th17 and pmel-1 Tc17 cells generated in vitro in the presence of the RORγ agonist, mice with melanoma tumors were protected for more than two months after tumor challenges of over three times, indicating that RORγ agonist-primed cells possessed a stem-like memory phenotype and provided a long-term protection against tumor challenges [ 117 ]. Furthermore, the RORα synthetic agonist SR1078 was reported to remarkably increase CD8+ T cell effector responses to anticancer immunity role [ 118 ]. Doxorubicin, which is developed from a metabolite of the bacterium Streptomyces peucetius var.…”
Section: Clock Drugs For the Immunotherapy Of Cancermentioning
confidence: 99%
“…Conssistent with a previous report, when co-infused TRP-1 Th17 and pmel-1 Tc17 cells generated in vitro in the presence of the RORγ agonist, mice with melanoma tumors were protected for more than two months after tumor challenges of over three times, indicating that RORγ agonist-primed cells possessed a stem-like memory phenotype and provided a long-term protection against tumor challenges [ 117 ]. Furthermore, the RORα synthetic agonist SR1078 was reported to remarkably increase CD8+ T cell effector responses to anticancer immunity role [ 118 ]. Doxorubicin, which is developed from a metabolite of the bacterium Streptomyces peucetius var.…”
Section: Clock Drugs For the Immunotherapy Of Cancermentioning
confidence: 99%
“…ATRA regulates differentiation of naive T cells to Treg cells through induction of FoxP3 transcription factor [229] , [246] , [247] and TGF-β potentiates this effect of ATRA [244] . Hence, RA blocks the differentiation of Th17 cells and induces Tregs in the presence of TGF-β by reciprocally down-regulating RORγt and activating FoxP3 expression in T cells [233] , [248] , [249] . Like a regulatory switch, ATRA largely inhibits Th17-mediated inflammation and autoimmunity [234] , [241] .…”
Section: Immune System Involvement and Retinoid Signaling Disorder In Covid-19mentioning
confidence: 99%
“…For example, RORα responds to metabolic changes and influences cholesterol synthesis pathways in cytotoxic T cells by inhibiting NF-κB target genes. The contributions of these activities to cytotoxic CD8+ T cells have been verified using RORα agonists 49 . Pharmacological stimulation of RORα using cholesterol sulfate and the synthetic agonist SR1078 activates downstream target genes of RORα, whereas the synthetic specific antagonist SR3335 functions as a selective inhibitor of RORα.…”
Section: Anti-inflammatory Mechanisms Involving Rorαmentioning
confidence: 97%